Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-25-065888
Filing Date
2025-07-03
Accepted
2025-07-03 20:00:07
Documents
1
Period of Report
2025-07-02

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2519824-1_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm2519824-1_4seq1.xml 4 11767
  Complete submission text file 0001104659-25-065888.txt   13347
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Issuer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address
Dambkowski Carl (Reporting) CIK: 0001983476 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41740 | Film No.: 251106792